argenex SE $ARGX Holdings Increased by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. increased its position in argenex SE (NASDAQ:ARGX) by 55.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 70,000 shares of the company’s stock after acquiring an additional 24,932 shares during the quarter. argenex accounts for 0.5% of Jefferies Financial Group Inc.’s holdings, making the stock its 19th largest position. Jefferies Financial Group Inc.’s holdings in argenex were worth $67,124,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in argenex by 3.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after buying an additional 83,568 shares during the last quarter. Jennison Associates LLC grew its holdings in argenex by 3.4% during the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock worth $173,411,000 after acquiring an additional 7,707 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in argenex by 1.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock worth $130,277,000 after acquiring an additional 2,579 shares during the last quarter. First Trust Advisors LP grew its holdings in argenex by 98.9% during the 1st quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after acquiring an additional 53,293 shares during the last quarter. Finally, Eagle Health Investments LP increased its position in argenex by 21.7% in the 1st quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock valued at $55,744,000 after acquiring an additional 13,606 shares during the period. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

ARGX has been the subject of several analyst reports. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of argenex in a research note on Wednesday, August 5th. Piper Sandler boosted their price objective on shares of argenex from $1,075.00 to $1,215.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. Royal Bank Of Canada reduced their price objective on shares of argenex from $1,100.00 to $1,025.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 20th. Morgan Stanley increased their price objective on argenex from $1,140.00 to $1,190.00 and gave the company an “overweight” rating in a report on Friday, October 23rd. Finally, DZ Bank reaffirmed a “buy” rating on shares of argenex in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,158.76.

argenex Stock Performance

Shares of ARGX opened at $977.58 on Thursday. argenex SE has a 52-week low of $661.85 and a 52-week high of $1,072.75. The business’s 50 day moving average price is $927.22 and its two-hundred day moving average price is $859.56. The firm has a market cap of $61.48 billion, a PE ratio of 34.11, a price-to-earnings-growth ratio of 0.90 and a beta of 0.48.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Friday, October 23rd. The company reported $7.80 EPS for the quarter, topping the consensus estimate of $7.44 by $0.36. The company had revenue of $1.75 billion during the quarter. argenex had a net margin of 31.66% and a return on equity of 47.70%. Research analysts predict that argenex SE will post 28.41 EPS for the current fiscal year.

argenex Company Profile

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.